Dynavax Technologies reported $345.2M in Current Liabilities for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Adma Biologics ADMA:US $ 31.57M 1.19M
Agenus AGEN:US $ 163.06M 6.12M
Amgen AMGN:US $ 12618M 268M
Astrazeneca AZN:US $ 21815M 925M
AstraZeneca AZN:LN 21815M 925M
Biogen BIIB:US $ 5018M 1071.4M
Biomarin Pharmaceutical BMRN:US $ 464.73M 25.69M
Bristol Myers Squibb BMY:US $ 20915M 1906M
Chimerix CMRX:US $ 23.27M 8.06M
Dynavax Technologies DVAX:US $ 345.2M 121M
Gilead Sciences GILD:US $ 9220M 662M
Glaxosmithkline GSK:US $ 37835M 13557M
Idera Pharmaceuticals IDRA:US $ 3.8M 1.07M
Minerva Neurosciences NERV:US $ 3.25M 0.43M
Nektar Therapeutics NKTR:US $ 104.98M 0.3M
Neurocrine Biosciences NBIX:US $ 285.7M 32.2M
Novartis NOVN:VX SF 27646M 2161M
Regeneron Pharmaceuticals REGN:US $ 3033.9M 26.3M
Sarepta Therapeutics SRPT:US $ 545.57M 90.6M
Vertex Pharmaceuticals VRTX:US $ 2556.2M 376M